 Sixty-six patients with Stage IIIB-IV non-small cell lung cancer were randomly assigned to IMN1207 or casein.Included were patients with a previous involuntary weight loss of ≥3%, Karnofsky status ≥70, and an estimated survival of > 3 months.Thirty-five lung cancer patients remained on study at six weeks.